Review Explores Eye Complications Linked to Popular GLP-1 Receptor Agonists

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for managing type 2 diabetes and obesity, offering significant metabolic benefits. However, as their use expands, a comprehensive understanding of all potential side effects, especially those affecting vision, becomes critical. This clinical review synthesizes existing evidence to delineate the spectrum and incidence of ocular adverse events associated with GLP-1 RA therapy.